Clinical analysis of developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep: A single tertiary care center experience in China

• Published in: Seizure (London, England) England), 2024-07, Vol.119, p.52-57
• Main Authors: Zhang, Yunjian, Li, Chunpei, Zhou, Yuanfeng, Yu, Lifei, Zhang, Linmei, Wang, Yi, Zhou, Shuizhen
• Format: Article
• Language: English
• Subjects: Anticonvulsants - therapeutic use; Child; Child, Preschool; China; DEE/EE-SWAS; EEG; Electroencephalography; Epilepsy; ESES; Female; Humans; Infant; Male; Retrospective Studies; Sleep - physiology; Status Epilepticus - drug therapy; Status Epilepticus - physiopathology; Tertiary Care Centers
• ISSN: 1059-1311; 1532-2688; 1532-2688
• DOI: 10.1016/j.seizure.2024.05.012

•Steroids, benzodiazepines, and ASMs are all effective treatments for patients with developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep.•Patients with structural etiologies or slow EEG backgrounds at the time of ESES recognition have a poor long-term prognosis.•Children with clinical or EEG responses showed improvement in cognition. To analyze the electroclinical features of patients with developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep (DEE/EE-SWAS) and study the efficacy of different therapies on seizure control, electroencephalogram (EEG) improvements of electrical status epilepticus during sleep (ESES), and cognition outcomes. Patients with DEE/EE-SWAS who underwent at least one follow-up EEG 3 months after therapy were retrospectively enrolled. The demographic and clinical characteristics of the patients were analyzed. Variables that influenced the outcomes were evaluated using logistic regression models. In total, 87 patients (47 males) were included. The median age at ESES recognition was 81.0 months (IQR 64.0, 96.0). Forty-six patients were diagnosed with self-limited focal epilepsies (SeLFEs) before ESES recognition, 24 with developmental and epileptic encephalopathies with spike-and-wave activation in sleep (DEE-SWAS), and 17 with other epilepsies. Steroids, benzodiazepines, and antiseizure medications (ASMs) were the initial treatment options for ESES. Patients with structural etiologies or slow EEG backgrounds at the time of ESES recognition were less likely to respond to treatment than other patients. However, only children with slow EEG backgrounds had lower odds of response in logistic regression models. Children with clinical or EEG response showed improvements in cognition. Steroids, benzodiazepines, and ASMs are effective treatments for patients with DEE/EE-SWAS. Children with structural etiologies or slow EEG backgrounds at the time of ESES recognition may have a poor long-term prognosis. The efficacy of seizure reduction and EEG improvement is associated with cognitive improvement.